Being Published in the Journal of Vascular and Interventional Radiology, a Premier Peer-Reviewed Journal, Speaks to the Quality and Impact of the ...
World’s first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for ...
The average one-year price target for Microbot Medical (NasdaqCM:MBOT) has been revised to $7.65 / share. This is an increase ...
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced today that the ...
HINGHAM, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, announced that LIBERTY was ...
Shares of Microbot Medical Inc. rocketed 67.3% toward a nine-month high on heavy volume in premarket trading Monday, after the pre-clinical medical device company announced an agreement with Stryker ...
Microbot Medical Inc. has announced the addition of two senior executives to enhance its U.S. commercial leadership team in preparation for the upcoming launch of its LIBERTY® Endovascular Robotic ...
Microbot Medical Inc. (MBOT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results